File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy

TitleA phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy
Authors
Issue Date2012
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy and Pharmacology, 2012, v. 70 n. 4, p. 583-590 How to Cite?
AbstractPURPOSE: The highest rates of gastric cancer occur in Eastern Asia. Fluoropyrimidine-based therapy is used initially in unresectable and metastatic disease, but no single standard of care exists following disease progression. Ixabepilone, an epothilone B analog, is a non-taxane microtubule-stabilizing agent with clinical activity across multiple tumor types approved by the United States Food and Drug Administration for treatment of metastatic breast cancer. METHODS: Asian patients with unresectable or metastatic gastric adenocarcinoma who had failed fluoropyrimidine-based chemotherapy received ixabepilone 40 mg/m(2) by 3-h intravenous infusion every 3 weeks. The primary endpoint was objective response rate (ORR). RESULTS: Fifty-two patients were treated (65.4 % men; median age: 56.5 years). The ORR was 15.4 % (95 % confidence interval [CI] 6.9-28.1); 8 patients achieved partial responses for a median duration of 3.1 months (95 % CI 2.6-4.1 months) and 26 patients (50.0 %) had stable disease. Median progression-free survival was 2.8 months (95 % CI 2.1-3.5 months). The most common grade 3 non-hematological toxicities were fatigue (9.6 %), decreased appetite (7.7 %), sensory neuropathy (5.8 %), and diarrhea (5.8 %). Grade 3/4 neutropenia occurred in 46.2 % of patients. CONCLUSIONS: Ixabepilone is active in Asian patients with advanced gastric cancer and shows a toxicity profile similar to those previously reported in other tumor types.
Persistent Identifierhttp://hdl.handle.net/10722/174152
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKim, YHen_US
dc.contributor.authorMuro, Ken_US
dc.contributor.authorYasui, Hen_US
dc.contributor.authorChen, JSen_US
dc.contributor.authorRyu, MHen_US
dc.contributor.authorPark, SHen_US
dc.contributor.authorChu, KMen_US
dc.contributor.authorChoo, SPen_US
dc.contributor.authorSanchez, Ten_US
dc.contributor.authorDelaCruz, Cen_US
dc.contributor.authorMukhopadhyay, Pen_US
dc.contributor.authorLainas, Ien_US
dc.contributor.authorLi, CPen_US
dc.date.accessioned2012-11-16T03:37:05Z-
dc.date.available2012-11-16T03:37:05Z-
dc.date.issued2012en_US
dc.identifier.citationCancer Chemotherapy and Pharmacology, 2012, v. 70 n. 4, p. 583-590en_US
dc.identifier.issn0344-5704-
dc.identifier.urihttp://hdl.handle.net/10722/174152-
dc.description.abstractPURPOSE: The highest rates of gastric cancer occur in Eastern Asia. Fluoropyrimidine-based therapy is used initially in unresectable and metastatic disease, but no single standard of care exists following disease progression. Ixabepilone, an epothilone B analog, is a non-taxane microtubule-stabilizing agent with clinical activity across multiple tumor types approved by the United States Food and Drug Administration for treatment of metastatic breast cancer. METHODS: Asian patients with unresectable or metastatic gastric adenocarcinoma who had failed fluoropyrimidine-based chemotherapy received ixabepilone 40 mg/m(2) by 3-h intravenous infusion every 3 weeks. The primary endpoint was objective response rate (ORR). RESULTS: Fifty-two patients were treated (65.4 % men; median age: 56.5 years). The ORR was 15.4 % (95 % confidence interval [CI] 6.9-28.1); 8 patients achieved partial responses for a median duration of 3.1 months (95 % CI 2.6-4.1 months) and 26 patients (50.0 %) had stable disease. Median progression-free survival was 2.8 months (95 % CI 2.1-3.5 months). The most common grade 3 non-hematological toxicities were fatigue (9.6 %), decreased appetite (7.7 %), sensory neuropathy (5.8 %), and diarrhea (5.8 %). Grade 3/4 neutropenia occurred in 46.2 % of patients. CONCLUSIONS: Ixabepilone is active in Asian patients with advanced gastric cancer and shows a toxicity profile similar to those previously reported in other tumor types.-
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280-
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic use-
dc.subject.meshEpothilones - adverse effects - therapeutic use-
dc.subject.meshFluorouracil - administration and dosage-
dc.subject.meshStomach Neoplasms - drug therapy - mortality-
dc.subject.meshTubulin Modulators - therapeutic use-
dc.titleA phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapyen_US
dc.typeArticleen_US
dc.identifier.emailChu, KM: chukm@hkucc.hku.hken_US
dc.identifier.authorityChu, KM=rp00435en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1007/s00280-012-1943-6-
dc.identifier.pmid22886073-
dc.identifier.pmcidPMC3456918-
dc.identifier.scopuseid_2-s2.0-84867576066-
dc.identifier.hkuros212338en_US
dc.identifier.volume70en_US
dc.identifier.issue4-
dc.identifier.spage583en_US
dc.identifier.epage590en_US
dc.identifier.isiWOS:000309201500012-
dc.publisher.placeGermany-
dc.identifier.citeulike11077811-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats